Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma

Journal Article · Sat Oct 01 00:00:00 EDT 2005 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2005.02.014· OSTI ID:20702151

Bourgier, Celine ^[1]; Coche-Dequeant, Bernard ^[1]; Fournier, Charles ^[2]; Castelain, Bernard ^[1]; Prevost, Bernard ^[1]; Lefebvre, Jean-Louis ^[3]; Lartigau, Eric ^[1]

---

1. Department of Radiotherapy, Centre Oscar Lambret, Lille (France)
2. Department of Biostatistics, Centre Oscar Lambret, Lille (France)
3. Department of Head and Neck Surgery, Centre Oscar Lambret, Lille (France)

Purpose: To evaluate the therapeutic results obtained with {sup 192}Ir low-dose-rate interstitial brachytherapy in T2N0 mobile tongue carcinoma. Patients and Methods: Between December 1979 and January 1998, 279 patients with T2N0 mobile tongue carcinoma were treated by exclusive low-dose-rate brachytherapy, with or without neck dissection. {sup 192}Ir brachytherapy was performed according to the 'Paris system' with a median total dose of 60 Gy (median dose rate, 0.5 Gy/h). Results: Overall survival was 74.3% and 46.6% at 2 and 5 years. Local control was 79.1% at 2 years and regional control, respectively, 75.9% and 69.5% at 2 and 5 years (Kaplan-Meier method). Systematic dissection revealed 44.6% occult node metastases, and histologic lymph node involvement was identified as the main significant factor for survival. Complication rate was 16.5% (Grade 3, 2.9%). Half of the patients presented previous and/or successive malignant tumor (ear-nose-throat, esophagus, or bronchus). Conclusion: Exclusive low-dose-rate brachytherapy is an effective treatment for T2 tongue carcinoma. Regional control and survival are excellent in patients undergoing systematic neck dissection, which is mandatory in our experience because of a high rate of occult lymph node metastases.

• OSTI ID: 20702151
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Vol. 63, Issue 2; Other Information: DOI: 10.1016/j.ijrobp.2005.02.014; PII: S0360-3016(05)00350-0; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
AUDITORY ORGANS
BRACHYTHERAPY
CARCINOMAS
DOSE RATES
ESOPHAGUS
IRIDIUM 192
LYMPH NODES
METASTASES
NECK
NOSE
PATIENTS
PHARYNX
RADIATION DOSES
TONGUE